Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
atomoxetine
|
| gptkbp:approves |
gptkb:United_States
|
| gptkbp:availableSizes |
10 mg
25 mg 60 mg 40 mg 18 mg |
| gptkbp:chemicalFormula |
C16H19NO
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:contraindication |
glaucoma
severe cardiovascular disorders monoamine oxidase inhibitors (MAOIs) |
| gptkbp:date |
2002
|
| gptkbp:dosageForm |
capsule
|
| gptkbp:drugInterdiction |
true
antidepressants CYP2D6 inhibitors blood pressure medications norepinephrine_reuptake_inhibitor |
| gptkbp:endOfLife |
5 to 24 hours
|
| gptkbp:healthcare |
take with or without food
do not crush or chew capsules report any mood changes |
| https://www.w3.org/2000/01/rdf-schema#label |
Strattera
|
| gptkbp:is_monitored_by |
weight
blood pressure heart rate mood changes |
| gptkbp:is_used_in |
cardiovascular effects
growth suppression psychiatric effects |
| gptkbp:isRecognizedFor |
children under 6 years
patients with a history of substance abuse patients with severe liver impairment |
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:marketedAs |
2002
|
| gptkbp:notableFeature |
gptkb:Strattera
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operationalStatus |
approved
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
fatigue
nausea vomiting decreased appetite irritability insomnia constipation dry mouth sweating sexual dysfunction |
| gptkbp:usedFor |
Attention Deficit Hyperactivity Disorder (ADHD)
|
| gptkbp:waterManagement |
urine
|